Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Brentuximab vedotin plus DHAP as effective salvage therapy in CD30+ peripheral T-cell lymphoma: A retrospective multicenter study

Thomas Weber, Sophy Denker, Julia Johanna Helmes et al. Nov 03, 2025 pp. 5425-5425 10.1182/blood-2025-5425

Abstract The prognosis of most nodal peripheral T-cell lymphomas (T-NHL) has not significantly improved over the past 25 years. Stage- or IP...

Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A single-center experience

Chen Zhang, Philip Papayanis, Parameswaran Venugopal et al. Nov 03, 2025 pp. 8056-8056 10.1182/blood-2025-8056

Abstract Introduction Chimeric antigen receptor T-cell therapy (CART) has emerged as a pivotal treatment option for pati...

Sphingosine-1-phosphate receptor modulators overcome FLT3 inhibitor resistance in Acute Myeloid Leukemia with FLT3-ITD and NRAS mutations through sphingosine kinase 1/AKT pathway downregulation.

Aditi Chatterjee, Moaath Mustafa Ali, Christopher Bailey et al. Nov 03, 2025 pp. 3288-3288 10.1182/blood-2025-3288

Abstract Background FLT3-ITD is present in acute myeloid leukemia (AML) in 25% of patients and is associated with poor treatment outcomes. FL...

The role of neutrophil extracellular traps in thrombosis of paroxysmal nocturnal hemoglobinuria

Mengting Che, Hui Liu, Yan Yang et al. Nov 03, 2025 pp. 1112-1112 10.1182/blood-2025-1112

Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by PIGA mutations, charact...

Advancing risk prediction in sickle cell disease through multi-task deep learning of mortality and intermediate risk factors

Gefei Lin, Rui Miao, Xin Tian et al. Nov 03, 2025 pp. 295-295 10.1182/blood-2025-295

Abstract Sickle cell disease (SCD) displays a wide spectrum of clinical severity that becomes more apparent with age. Transplantation and ge...

EZH2 oncogenic mutation disrupts germinal center B cell dynamics and promotes early lymphomagenic behaviors

Kibaek Choe, Chanhong Min, Ioannis Karagiannidis et al. Nov 03, 2025 pp. 1479-1479 10.1182/blood-2025-1479

Abstract A major clinical challenge in germinal center (GC)-derived lymphomas, such as follicular lymphoma (FL) and diffuse large B-cell lym...

The CSMD1 gene is involved in hematopoietic stem cell HSC pruning in patients with acquired immune-mediated aplastic anemia

Antonio Risitano, Deniz Ece Kaya, Simona Iacobelli et al. Nov 03, 2025 pp. 4982-4982 10.1182/blood-2025-4982

Abstract Introduction Somatic mutations in Hematopoietic Stem Cells and Progenitors (HSC/HCP) are very frequent in patie...

Interferon-induced cell senescence as a novel mechanism of eculizumab resistance in transplant associated thrombotic microangiopathy

Aaron Webster, Kana Mizuno, Nathan Luebbering et al. Nov 03, 2025 pp. 509-509 10.1182/blood-2025-509

Abstract Eculizumab significantly increased survival in patients with transplant associated thrombotic microangiopathy (TA-TMA), however one...

Sickle cell disease treatment with arginine therapy (STArT) – results of a phase-3 randomized controlled trial

Claudia Morris, Fahd Ahmad, Gladstone Airewele et al. Nov 03, 2025 pp. 616-616 10.1182/blood-2025-616

Abstract Background: Vaso-occlusive pain episodes (VOE) are the leading cause of emergency department (ED) visits and hospitalizations for p...

Mechanical thrombectomy: Long-term risk for venous thromboembolism recurrence

Benjamin Djulbegovic, Sydney Anuskiewicz, Joe Mazur et al. Nov 03, 2025 pp. 743-743 10.1182/blood-2025-743

Abstract Introduction Venous thromboembolism (VTE) represents a major cause of cardiovascular morbidity, with mechanical thrombectomy (MT) i...

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

William D. Marrero, Mina Abdelmalek, Farah Al Haj et al. Nov 03, 2025 pp. 5179-5179 10.1182/blood-2025-5179

Abstract Introduction: AML is risk categorized based on the presence and cooperation of certain cytogenetics and molecular characteristics....

Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)

Sueh-Li Lim, John Reynolds, Lucy Pemberton et al. Nov 03, 2025 pp. 5842-5842 10.1182/blood-2025-5842

Abstract Introduction: Real-world survival for TI NDMM patients (pts) is inferior to transplant eligible (TE)-NDMM pts with median OS of 48...

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Jay Hydren, Rachel Jensen, Jorge Arturo Hurtado Martinez et al. Nov 03, 2025 pp. 6354-6354 10.1182/blood-2025-6354

Abstract Background Teclistamab (Tec) and Talquetamab (Tal) are the two first FDA approved bispecific antibodies (BsAb) for the treatment of...

ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia

Sae Ishimaru, Gwenaëlle Gueguen, Seth Karol et al. Nov 03, 2025 pp. 1656-1656 10.1182/blood-2025-1656

Abstract Background Despite improvements in the treatment of children with acute myeloid leukemia (AML) with modern multi-agent therapy, sur...

Social isolation and patient-reported and healthcare utilization in adults with sickle cell disease

Richard Newcomb, Anushka Fernandes, Braelyn Wekwerth et al. Nov 03, 2025 pp. 4450-4450 10.1182/blood-2025-4450

Abstract Background Adults with sickle cell disease (SCD) endure immense physical and psychological suffering related to their illness. Pati...

Post-transplant maintenance with revumenib in children with HOX-driven AML

Branko Cuglievan, Olayinka Okeleji, Samanta Catueno et al. Nov 03, 2025 pp. 3461-3461 10.1182/blood-2025-3461

Abstract Background: Children with HOX-driven AML, including KMT2A or NUP98 rearrangements (KMT2Ar, NUP98r), have poor outcomes, particularly...

Distinct predictors of mortality and conduction disease in AL cardiac amyloidosis

Ali Mushtaq, Ahmad Safdar, Ahmed Mohamed et al. Nov 03, 2025 pp. 3958-3958 10.1182/blood-2025-3958

Abstract Introduction: For hematologists managing light-chain (AL) cardiac amyloidosis, risk stratification is complicated by the dual threat...

Trial in progress: Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) nathali-01

Jeremy Abramson, Aravind Ramakrishnan, Emmanuel Bachy et al. Nov 03, 2025 pp. 3731-3731 10.1182/blood-2025-3731

Abstract Background: Despite significant advances in the treatment of B-cell non-Hodgkin's lymphoma, new treatment approaches are needed for...

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

Krina Patel, Lin Wang, Rashmi Bhatnagar et al. Nov 03, 2025 pp. 5769-5769 10.1182/blood-2025-5769

Abstract Introduction: Many treatments for relapsed/refractory multiple myeloma (RRMM) require treat-to-progression, which can result in cum...

Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)

George Cholack, Dominic Edelmann, Janek Walker et al. Nov 03, 2025 pp. 5301-5301 10.1182/blood-2025-5301

Abstract Over the past decade, classification systems using high-throughput genetic data have been developed to identify molecular subtypes...

Racial disparities in treatment initiation and early outcomes among patients with multiple myeloma: A real-world, multi-institutional cohort study

Ali Sanjari Moghaddam, Ameera Syed, Hannah Ruby et al. Nov 03, 2025 pp. 7560-7560 10.1182/blood-2025-7560

Abstract Background: Despite therapeutic advances in multiple myeloma (MM), racial disparities in treatment access and outcomes persist. Pri...

The early discharge clinic: A safe and efficient model for intensive outpatient management of hematologic malignancies

Christina Mallilo, Joo Yeon Seo, Brittany Mockler et al. Nov 03, 2025 pp. 7957-7957 10.1182/blood-2025-7957

Abstract Hematologic malignancies often necessitate complex treatment regimens that can result in prolonged hospitalizations, increasing hea...

Outcomes of relapsed or refractory mature T/NK-cell lymphomas in the era of novel agents: A nationwide observational Study in Japan

Hideki Uryu, Tsuyoshi Muta, Mitsumasa Watanabe et al. Nov 03, 2025 pp. 1865-1865 10.1182/blood-2025-1865

Abstract Background: Mature T-cell and natural killer-cell lymphomas (MTNKLs) are often refractory to conventional treatment and associated...

Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia

Roberta S. Azevedo, Christopher Manuel, Tapan Kadia et al. Nov 03, 2025 pp. 1634-1634 10.1182/blood-2025-1634

Abstract Background: Core binding factorfactor (CBF) leukemias are defined by presence of unique translocation events; t(8;21)(RUNX1::RUNX1T...

National cross-sectional Study to explore current state of patient awareness of multiple myeloma (MM) disease basics and its management: Identifying gaps and associations

Kenyot'a Russell, Saurav Das, Dhaani Ailawadhi et al. Nov 03, 2025 pp. 4587-4587 10.1182/blood-2025-4587

Abstract Background: MM is the second most common hematologic malignancy, which despite significant therapeutic advancements, remains incura...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page